Skye Bioscience Q2 2026 Earnings Report

Skye Bioscience EPS Results

• Actual EPS: -$0.27
• Consensus EPS: -$0.29
• Beat/Miss: Beat by +$0.02
• One Year Ago EPS: N/A

Skye Bioscience Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Skye Bioscience Announcement Details

• Quarter: Q2 2026
• Date: 8/14/2026
• Time: Before Market Opens
• Conference Call Date: Friday, August 14, 2026
• Conference Call Time: 4:00PM ET

Skye Bioscience (NASDAQ:SKYE) is a clinical-stage biopharmaceutical company focused on developing medicines that modulate the endocannabinoid system, a network involved in metabolism, inflammation and other physiological processes. The company’s research is centered on therapies designed to influence cannabinoid receptors outside the central nervous system, with the goal of addressing disease while avoiding certain side effects associated with earlier centrally acting cannabinoid drugs.

Skye’s lead investigational product is nimacimab, a monoclonal antibody that targets the cannabinoid receptor 1 (CB1). The company is evaluating nimacimab in metabolic diseases, including obesity and metabolic dysfunction-associated steatohepatitis (MASH), also known as metabolic dysfunction-associated steatotic liver disease in broader disease classifications. The program is intended to address metabolic dysfunction and inflammation through peripheral CB1 modulation.

Historically, Skye also advanced SBI-100 Ophthalmic Emulsion, an investigational topical therapy designed to modulate CB1 signaling for ophthalmic conditions such as glaucoma. The company has since concentrated its development strategy on metabolic and inflammatory diseases. Skye is headquartered in San Diego, California, and has been led by co-founder and Chief Executive Officer Punit Dhillon.